SCHEDULE: Coastlands Capital Discloses 5.1% Stake in Neuphoria
Beneficial Ownership Disclosure
Coastlands Capital LP and related entities have reported a 5.1% beneficial ownership stake in Neuphoria Therapeutics Inc., holding 120,000 shares.
Summary
- Coastlands Capital LP, along with Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry, collectively reported beneficial ownership of 120,000 shares of Neuphoria Therapeutics Inc. Common Stock.
- This ownership represents 5.1% of Neuphoria Therapeutics Inc.'s outstanding Common Stock.
- The calculation of beneficial ownership is based on 2,357,613 shares of Common Stock issued and outstanding as of September 29, 2025, as reported by Neuphoria Therapeutics Inc. in its Annual Report on Form 10-K.
- The reporting persons share both voting and dispositive power over all 120,000 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of beneficial ownership without explicit positive or negative operational or financial news.
Future Outlook
NA
Industry Context
This filing indicates an institutional investor, Coastlands Capital, has taken a significant passive stake in Neuphoria Therapeutics Inc. Such disclosures are common and reflect investment firms' portfolio adjustments based on their market analysis and investment strategies. It does not provide specific insights into Neuphoria's operational performance or industry trends beyond the fact that an investment firm sees value in holding its shares.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by Coastlands Capital may be viewed positively by other investors, potentially signaling confidence in Neuphoria Therapeutics Inc.'s prospects. It also increases the institutional ownership base.
Key Dates
| Date | Description |
|---|---|
| 2025-09-29 | Date as of which Neuphoria Therapeutics Inc. reported 2,357,613 shares of Common Stock issued and outstanding in its Annual Report on Form 10-K. |
| 2025-11-05 | Date of event which required the filing of this statement. |
| 2025-11-05 | Date the Schedule 13G was signed and filed. |
Keywords
Neuphoria Therapeutics Inc., Coastlands Capital LP, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.